MESOBLAST LTD- SPON ADR (MESO) Stock Fundamental Analysis

NASDAQ:MESO • US5907174016

16.88 USD
-0.03 (-0.18%)
At close: Feb 20, 2026
16.91 USD
+0.03 (+0.18%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

MESO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. MESO may be in some trouble as it scores bad on both profitability and health. MESO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year MESO has reported negative net income.
  • MESO had a negative operating cash flow in the past year.
  • MESO had negative earnings in each of the past 5 years.
  • MESO had a negative operating cash flow in each of the past 5 years.
MESO Yearly Net Income VS EBIT VS OCF VS FCFMESO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • With an excellent Return On Assets value of -13.02%, MESO belongs to the best of the industry, outperforming 82.53% of the companies in the same industry.
  • MESO's Return On Equity of -17.10% is amongst the best of the industry. MESO outperforms 85.41% of its industry peers.
Industry RankSector Rank
ROA -13.02%
ROE -17.1%
ROIC N/A
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
MESO Yearly ROA, ROE, ROICMESO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

1.3 Margins

  • MESO's Gross Margin of 70.17% is amongst the best of the industry. MESO outperforms 81.77% of its industry peers.
  • In the last couple of years the Gross Margin of MESO has grown nicely.
  • MESO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
MESO Yearly Profit, Operating, Gross MarginsMESO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MESO has more shares outstanding
  • Compared to 5 years ago, MESO has more shares outstanding
  • MESO has a better debt/assets ratio than last year.
MESO Yearly Shares OutstandingMESO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MESO Yearly Total Debt VS Total AssetsMESO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 5.26 indicates that MESO is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.26, MESO is in the better half of the industry, outperforming 73.13% of the companies in the same industry.
  • A Debt/Equity ratio of 0.12 indicates that MESO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.12, MESO is doing worse than 62.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 5.26
ROIC/WACCN/A
WACC9.1%
MESO Yearly LT Debt VS Equity VS FCFMESO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • MESO has a Current Ratio of 1.99. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.99, MESO is doing worse than 75.62% of the companies in the same industry.
  • MESO has a Quick Ratio of 1.77. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.77, MESO is not doing good in the industry: 76.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.77
MESO Yearly Current Assets VS Current LiabilitesMESO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.99% over the past year.
  • The Revenue for MESO has decreased by -26.56% in the past year. This is quite bad
  • Measured over the past years, MESO shows a very negative growth in Revenue. The Revenue has been decreasing by -15.43% on average per year.
EPS 1Y (TTM)21.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-26.56%
Revenue growth 3Y-38.44%
Revenue growth 5Y-15.43%
Sales Q2Q%N/A

3.2 Future

  • MESO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.54% yearly.
  • MESO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 112.74% yearly.
EPS Next Y-279.39%
EPS Next 2Y-77.14%
EPS Next 3Y14.17%
EPS Next 5Y43.54%
Revenue Next Year-23.22%
Revenue Next 2Y44.23%
Revenue Next 3Y139.98%
Revenue Next 5Y112.74%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MESO Yearly Revenue VS EstimatesMESO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
MESO Yearly EPS VS EstimatesMESO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MESO. In the last year negative earnings were reported.
  • Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MESO Price Earnings VS Forward Price EarningsMESO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MESO Per share dataMESO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MESO's earnings are expected to grow with 14.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-77.14%
EPS Next 3Y14.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MESO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (2/20/2026, 8:00:01 PM)

After market: 16.91 +0.03 (+0.18%)

16.88

-0.03 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-29
Earnings (Next)02-25
Inst Owners18.86%
Inst Owner Change11.2%
Ins Owners17.95%
Ins Owner ChangeN/A
Market Cap2.18B
Revenue(TTM)7.50M
Net Income(TTM)-102.14M
Analysts82
Price Target18.46 (9.36%)
Short Float %3.22%
Short Ratio12.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.85%
PT rev (3m)17.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.57%
EPS NY rev (1m)0%
EPS NY rev (3m)63.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 126.64
P/FCF N/A
P/OCF N/A
P/B 3.65
P/tB 85.02
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.13
BVpS4.63
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.02%
ROE -17.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.17%
FCFM N/A
ROA(3y)-12.8%
ROA(5y)-13.09%
ROE(3y)-17.24%
ROE(5y)-17.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y26.94%
F-Score6
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 3.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.77
Altman-Z 5.26
F-Score6
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.02%
Cap/Sales(5y)7.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-279.39%
EPS Next 2Y-77.14%
EPS Next 3Y14.17%
EPS Next 5Y43.54%
Revenue 1Y (TTM)-26.56%
Revenue growth 3Y-38.44%
Revenue growth 5Y-15.43%
Sales Q2Q%N/A
Revenue Next Year-23.22%
Revenue Next 2Y44.23%
Revenue Next 3Y139.98%
Revenue Next 5Y112.74%
EBIT growth 1Y-23.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.38%
EBIT Next 3Y95.39%
EBIT Next 5Y101.36%
FCF growth 1Y-3.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.09%
OCF growth 3YN/A
OCF growth 5YN/A

MESOBLAST LTD- SPON ADR / MESO FAQ

What is the ChartMill fundamental rating of MESOBLAST LTD- SPON ADR (MESO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MESO.


What is the valuation status for MESO stock?

ChartMill assigns a valuation rating of 0 / 10 to MESOBLAST LTD- SPON ADR (MESO). This can be considered as Overvalued.


Can you provide the profitability details for MESOBLAST LTD- SPON ADR?

MESOBLAST LTD- SPON ADR (MESO) has a profitability rating of 3 / 10.